Study Shows Unrelated Marrow Transplantation Offers Hope Of Cure For People Diagnosed With Chronic Myeloid Leukemia

April 01, 1998

Fred Hutchinson Cancer Research Center Study Finds Survival Rates are Comparable to HLA-Matched Sibling Donors When Treated Under Outlined Optimal Conditions

Seattle - Study demonstrates that marrow transplantation using HLA-matched unrelated donors can be safe and effective therapy for patients with chronic myeloid leukemia (CML) in chronic phase. Seattle researchers also believe that transplantation should not be limited to younger people, under the age of 40 years. Fred Hutchinson Cancer Research Center researchers published the results of their study in the April 2, 1998, issue of The New England Journal of Medicine.

Transplantation has been shown to be the cure for many blood disorders and inherited diseases, including CML. One obstacle has always been the identification of a suitably matched donor. Previously, it was believed that only those CML patients with an HLA-matched sibling donor had an option for curative treatment. This study concludes that marrow transplantation from an HLA-matched unrelated donor can be the treatment of choice for many CML patients and should be considered early in the course of disease to optimize outcome. According to researchers, this study showed that people diagnosed with CML who undergo an unrelated HLA-matched transplant have a comparable rate of survival to those diagnosed with the same disease who undergo an HLA-matched sibling marrow transplant.

The research team, led by John Hansen, M.D., head of Human Immunogenetics at the Fred Hutchinson Cancer Research Center, reviewed the results of 196 patients transplanted with unrelated donor marrow between May 1985 and December 1994. All patients were under 55 years of age and had been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. The overall survival rate was 57 percent, but for patients less than 50 years old transplanted from an HLA matched donor within one year from diagnosis the survival rate was 74 percent. The overall survival rate for similar patients who have undergone transplant with a matched sibling donor is 77 percent. The factors associated with a better survival following an unrelated donor transplant included transplantation within the first year of diagnosis, selection of an HLA-matched donor and post-transplant supportive care aimed at protecting patients from viral and fungal infections.

"These conditions offer the best chance for survival, says Hansen. "The time factor underscores the importance of planning treatment early and performing an HLA family study to determine if the patient has an HLA-matched related donor. If an HLA-matched donor cannot be found within the family, an unrelated donor search should be started."

According to the analysis, graft-versus-host disease (GVHD) still is an issue for patients receiving an unrelated donor transplant, especially if HLA matching is not complete. Researchers believe that GVHD can be minimized in male patients by the use of an HLA-matched male donor, and the risk of chronic GVHD can be minimized in male and female patients by the use of male donors or females who have never given birth.

Previous studies have shown the incidence of graft failure was higher than expected following an unrelated donor transplant for patients with CML. Researchers believe this was a result of undetected HLA incompatibility in the donor. In the current study the marrow was not T-cell depleted (T-cells are the white blood cells that initiate immune responses) and the risk of graft failure was lower than originally anticipated. The patients in this study, however received unmodified marrow grafts replete of donor T cells, whereas the previous studies reporting higher rates of graft failure performed T cell-depletion of donor marrow prior to transplantation.

This study was funded by the National Institutes of Health. The National Marrow Donor Program, and other registries, make it possible for patients to find donors.
-end-


Fred Hutchinson Cancer Research Center

Related Transplantation Articles from Brightsurf:

A revolutionary new treatment alternative to corneal transplantation
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.

Fewer complications after organ transplantation
A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

Elderly patients also benefit from kidney transplantation
So far, kidney transplantation has generally not been offered to elderly patients (>75 years) because of the perioperative risks.

New material will allow abandoning bone marrow transplantation
Scientists from the National University of Science and Technology 'MISIS' developed nanomaterial, which will be able to restore the internal structure of bones damaged due to osteoporosis and osteomyelitis.

Fewer medical tests -- timely listing for transplantation
Younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.

Uterus transplantation -- ethically just as problematic as altruistic surrogacy
In 2014, the first child to have been gestated in a donated uterus was born.

Advancing transplantation: Hepatitis C-infected organs safe for transplantation when followed by antiviral treatment
Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine.

Transplantation followed by antiviral therapy cured hepatitis C
Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year.

The Journal of Heart and Lung Transplantation: 50 years of heart transplantation progress
This month marks the 50th anniversary of the world's first human heart transplant performed at Groote Schuur Hospital in Cape Town by South African surgeon, Christiaan Barnard.

Older donor lungs should be considered for transplantation
With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published online today in The Annals of Thoracic Surgery.

Read More: Transplantation News and Transplantation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.